Accéder au contenu
Merck

Microglia replacement by microglia transplantation (Mr MT) in the adult mouse brain.

STAR protocols (2021-07-27)
Zhen Xu, Bo Peng, Yanxia Rao
RÉSUMÉ

Mutations in microglia may cause brain disorders. Replacement of dysfunctional microglia by allogeneic wild-type microglia from bone marrow transplantation (Mr BMT) or peripheral blood can correct the gene deficiency at the brain-wide scale but cannot achieve precise replacement at specific brain regions. Here, we introduce a strategy with potential clinical relevance-microglia replacement by microglia transplantation (Mr MT), combining tamoxifen-induced ablation of Mr BMT cells and intracranial injection of microglia to mouse brain, to achieve region-sepcific microglia replacement. The original abbreviation of this microglia replacement strategy is mrMT. We hereby change the name to Mr MT. For complete details on the use and execution of this protocol, please refer to Xu et al. (2020).

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Diméthylsulfoxyde, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
Cholestérol, Sigma Grade, ≥99%
Sigma-Aldrich
N-Acetyl-L-cysteine, BioReagent, suitable for cell culture
Sigma-Aldrich
L-cystéine, 97%
Sigma-Aldrich
apo-Transferrine human, powder, BioReagent, suitable for cell culture, ≥98% (agarose gel electrophoresis)
Sigma-Aldrich
Acide oléique, BioReagent, suitable for cell culture
Sigma-Aldrich
Xylazine hydrochloride, ≥99.0% (HPLC)
Sigma-Aldrich
Acide cis-11-Eicosénoique, ≥99% (capillary GC)
Sigma-Aldrich
Meloxicam sodium salt hydrate, ≥98% (HPLC)